编者按:随着新药研发不断向更复杂的靶点、更具挑战性的作用机制和更多元的分子类型拓展,如何更高效地将科学发现转化为可推进的研发项目,正成为全球生物医药创新面临的重要课题。从早期靶点研究、苗头化合物发现到先导化合物优化,研发团队不仅需要高质量的数据和多学科技术能力,也需要更加紧密协同的研发体系,以持续缩短决策和迭代周期。
为了更好地支持全球创新者加速药物发现与开发,药明康德通过一体化CRDMO平台,将研究、开发与生产能力有机衔接,并依托全球网络和本地化专业团队,为不同阶段的研发项目提供灵活支持。Crelux作为药明康德全球药物发现网络的重要组成部分,也从最初专注于结构生物学,逐步发展成为覆盖苗头化合物发现和先导化合物优化的多学科药物发现平台。
近日,药明康德旗下Crelux总经理Thomas Meins博士接受欧洲行业媒体VC Magazin采访,分享了Crelux加入药明康德十年来的发展历程,并深入探讨了一体化研发能力如何助力创新企业加速药物发现、提升资本使用效率,以及欧洲生物医药生态如何进一步缩短从科学发现到商业化转化的周期。
以下是报道全文,点击“阅读原文/Read More”即可访问原文页面。
![]()
VC Magazin:十年前,药明康德收购了Crelux。Crelux的特长是基于生物大分子的结构进行新药发现,是该领域的全球领先企业之一。加入药明康德后,Crelux经历了怎样的发展?过去十年,双方共同取得了哪些重要进展?
Thomas Meins博士:十年前,Crelux加入药明康德,成为其全球合同研究、开发和生产服务(CRDMO)体系的重要组成部分。当时,我们不仅希望保留既有业务与能力,更希望为团队进一步成长和发展创造更好的条件。
过去十年,Crelux已深度融入药明康德。我们扎根于慕尼黑当地的生命科学创新生态,同时成为药明康德全球药物发现网络的重要枢纽。
我们的科研人员与欧洲及全球各地的同事紧密协作,通过跨学科的专业互补,共同应对日益复杂的科学挑战。在这一过程中,Crelux从一家专注于结构生物学的公司,逐步发展为集苗头化合物发现(hit identification)和先导化合物优化(lead optimization)的多学科药物发现中心。我们整合了结构生物学、蛋白质组学和筛选等领域的技术与科研能力,致力于应对复杂靶点和新模态(modality)药物的研发挑战。
过去十年,我们在慕尼黑的科研团队从30人增至100余人,场地面积从约700平方米扩大至约3000平方米。慕尼黑基地与药明康德全球其他设施协同,帮助客户将前沿创新理念逐步转化为具备规模化潜力的解决方案。如今,慕尼黑也是药明康德欧洲总部所在地,进一步彰显了其在药明康德全球战略布局中的重要性。
VC Magazin:一项科学发现要成为真正能够用于患者的新疗法,还需要经过研究、验证和开发等多个步骤。你们如何帮助研发团队加快这一过程?
Thomas Meins博士:药物发现是一个不断学习、反复验证的过程:产生数据,从中得出结论,再决定下一步怎么做。这个过程推进得越快,决策依据越充分,有潜力的分子就越有机会更快地发展为真正的治疗方案。
凭借多元的技术平台和深厚的科研专长,我们能够为研发项目提供坚实的数据,帮助客户在早期阶段更有依据地作出“继续或终止”(go/no-go)的决策,以降低研发风险。同时,客户无需投入大量资金构建内部能力或组建专业团队。
我们积极引入前沿技术,并将其转化为让客户能直接使用的服务能力,免去了客户在相关基础设施上的重资产投入。在合作中,客户既能利用药明康德全球科研网络中不同领域的技术和专业经验,也能与扎根当地、按照欧洲标准运营的团队直接沟通、开展工作。
随着项目推进,我们还能为客户提供从药物发现、开发到商业化生产的全链条支持,帮助客户衔接各个阶段的工作。
![]()
图片来源:123RF
VC Magazin:生物科技初创企业往往资金和人员有限,需要取得关键研发成果,才能吸引投资、继续推进项目。药明康德如何帮助这些企业降低研发风险,更高效地取得投资者关注的阶段性成果?
Thomas Meins博士:对于生物科技初创企业而言,研发时间和资金使用效率都至关重要。大多数初创企业很难仅靠自有资金,将一项有潜力的科学发现推进到商业化生产。
因此,在关键节点获得所需的数据,是吸引投资、推动项目继续发展的重要条件——这也正是许多极具潜力的科研项目陷入停滞的瓶颈所在。
通过与药明康德合作,新兴生物科技公司无需承担从零搭建各项研发平台的成本,就能获得广泛的科研与技术支持。支持项目的团队也可以随着研发重点的变化灵活调整。这让企业能够将更多资金集中投入到核心科学研究,并在同一合作伙伴的支持下,将项目持续推进到下一个阶段。
VC Magazin:生物科技创新需要科研机构、企业、投资者和研发服务机构等多方参与。展望未来5至10年,你认为欧洲在推动这些力量协作、将科学发现发展为新疗法方面,最大的机会在哪里?
Thomas Meins博士:欧洲最核心的优势在于深厚的科研积累、多元化的研究,以及对科学探索的长期坚持。从早期mRNA研究促成了突破性疫苗的问世,再到数十年的GLP-1研究最终转化为今日的重磅药物,这些成果都充分证明了科学探索的长期坚持所能带来的价值。
接下来,欧洲亟需进一步加快从“科学构想”到“商业化”的转化。欧洲不缺好的科学构想,但要让这些科研成果最终能够成为惠及患者的治疗方案,还需要更强的开发和规模化能力。这离不开本土化的基础设施、成熟的制造工艺以及真正扎根当地的合作伙伴。
这正是药明康德发挥切实作用的地方。药明康德在欧洲的布局,可以为药物开发的不同阶段提供灵活的技术和产能支持,帮助有潜力的科学发现继续在当地推进,并构建推动项目后续开发和生产所需的能力。
与此同时,投资者也越来越认可欧洲高质量的科研创新,以及背后更为审慎、高效的资金使用方式。如果欧洲能够进一步加快从“科学构想”到“商业化”的转化进程,我对未来十年的发展充满信心。
VC Magazin:非常感谢您接受采访。
‘What needs to catch up is the speed of translation from idea to commerce’
The challenge in drug discovery is not simply generating new ideas, but translating the right science into viable development programs faster and with greater confidence. As targets and therapeutic modalities become more complex, success increasingly depends on shorter learning cycles, multidisciplinary expertise, and closely connected R&D capabilities. In a recent interview with European industry publication VC Magazin, Dr. Thomas Meins, General Manager and Site Head of Crelux, a WuXi AppTec company, reflected on Crelux’s evolution within WuXi AppTec’s global network and discussed how integrated R&D models can accelerate discovery, improve capital efficiency, and help narrow the gap between scientific innovation and commercialization.
![]()
VC Magazin: Ten years ago, WuXi AppTec acquired Crelux, a global leader in structure-based drug discovery. How has the company evolved under WuXi AppTec’s umbrella, and what milestones have you jointly achieved since then?
Meins:When Crelux joined WuXi AppTec ten years ago and became part of the global Contract Research, Development, and Manufacturing Organization (CRDMO), the goal was never simply to preserve what we had built, but to create conditions in which it could grow further. Today, Crelux operates as an integral part of WuXi AppTec, and is firmly embedded in Munich’s local ecosystem and at the same time a pillar of the discovery research network that is operating globally. Our scientists collaborate seamlessly with colleagues in Europe and around the world, combining complementary expertise to solve increasingly complex scientific challenges.We have evolved from a structural biology company into a multidisciplinary discovery hub for hit identification and lead optimisation, integrating complementary technologies and scientific expertise across structural biology, proteomics, and advanced screening to address complex targets and modalities.Our Munich team has grown from 30 to over 100 scientists, our site from 700 to 3,000 square metres in only ten years. Together with facilities around the world, the Munich site supports clients in translating innovative ideas into scalable solutions.Munich has also become WuXi AppTec’s European headquarters, reflecting the strategic importance the region holds within the global organisation.
VC Magazin: How do you contribute to accelerating the translation of scientific research into new therapies?
Meins:Drug discovery is a series of learning cycles: generate data, draw conclusions, make the next decision. The faster and more confidently those cycles run, the sooner a promising molecule becomes a real therapy.Our breadth of technologies and scientific expertise helps reduce development risk by providing a robust data foundation for earlier, better-informed go/no-go decisions, while avoiding the capital investment required to build these capabilities and expertise in-house.We adopt emerging technologies early and make them accessible to customers without requiring them to invest in the infrastructure themselves.They have the opportunity to draw on the full depth of WuXi AppTec’s integrated global expertise while working with a locally rooted team, operating to European standards.And as their programmes grow, they can scale with our help from discovery through development to commercial manufacturing.
![]()
Image Source: 123RF
VC Magazin: How does WuXi AppTec support biotech start-ups in reducing development risks and reaching investor-relevant milestones more efficiently?
Meins:For biotech start-ups, timing and capital efficiency are everything. Most cannot self-fund the journey from promising science to commercial scale, and generating the right data at the right time is essential for attracting investment and advancing programmes. This is where promising science too often stalls.Working with us, emerging companies access a broad range of capabilities without bearing the cost of building them, supported by a team that adapts to changing priorities.That frees capital for science and allows them to move from one stage to the next with a single trusted partner.
VC Magazin: Where do you see the greatest opportunities for the European biotech ecosystem over the next five to ten years?
Meins:Europe’s greatest strength is the depth, diversity, and persistence of its scientific research. The path from early mRNA science to transformative vaccines, or from decades of GLP-1 work to today’s medicines, shows what sustained scientific conviction can achieve. What needs to catch up is the speed of translation from idea to commerce.Europe excels at generating scientific ideas; it needs to become equally strong at developing and scaling them into treatments for patients. That requires local infrastructure, manufacturing expertise, and partners genuinely anchored on the ground.This is where WuXi AppTec plays a concrete role: providing end-to-end flexibility and capacity from within Europe, keeping promising discoveries in the region, and building the capabilities to advance them. Investors are increasingly recognising both the quality of European science and the disciplined use of capital behind it. If Europe can close that gap, I am genuinely optimistic about the decade ahead.
VC Magazin: Thank you very much.
免责声明:本文仅作信息交流之目的,文中观点不代表药明康德立场,亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导,请前往正规医院就诊。
版权说明:欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”,获取转载须知。
![]()
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.